Annual CFO
-$120.80 M
-$47.21 M-64.15%
31 December 2023
Summary:
AnaptysBio annual cash flow from operations is currently -$120.80 million, with the most recent change of -$47.21 million (-64.15%) on 31 December 2023. During the last 3 years, it has fallen by -$74.88 million (-163.07%). ANAB annual CFO is now -927.23% below its all-time high of $14.60 million, reached on 31 December 2014.ANAB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$10.09 M
+$11.23 M+52.68%
01 September 2024
Summary:
AnaptysBio quarterly cash flow from operations is currently -$10.09 million, with the most recent change of +$11.23 million (+52.68%) on 01 September 2024. Over the past year, it has increased by +$24.26 million (+70.63%). ANAB quarterly CFO is now -126.85% below its all-time high of $37.58 million, reached on 31 December 2020.ANAB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$103.01 M
+$26.38 M+20.39%
01 September 2024
Summary:
AnaptysBio TTM cash flow from operations is currently -$103.01 million, with the most recent change of +$26.38 million (+20.39%) on 01 September 2024. Over the past year, it has increased by +$17.79 million (+14.72%). ANAB TTM CFO is now -707.43% below its all-time high of $16.96 million, reached on 30 September 2021.ANAB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANAB Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +70.6% | +14.7% |
| 3 y3 years | -163.1% | +60.1% | -124.3% |
| 5 y5 years | -73.8% | +36.2% | -48.2% |
ANAB Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -163.1% | at low | at high | +72.9% | -135.6% | +22.8% |
| 5 y | 5 years | -753.3% | at low | -126.8% | +72.9% | -707.4% | +22.8% |
| alltime | all time | -927.2% | at low | -126.8% | +72.9% | -707.4% | +22.8% |
AnaptysBio Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$10.09 M(-52.7%) | -$103.01 M(-20.4%) |
| June 2024 | - | -$21.32 M(-42.8%) | -$129.40 M(-3.1%) |
| Mar 2024 | - | -$37.25 M(+8.5%) | -$133.49 M(+10.5%) |
| Dec 2023 | -$120.80 M(+64.1%) | -$34.35 M(-5.8%) | -$120.80 M(+24.4%) |
| Sept 2023 | - | -$36.47 M(+43.5%) | -$97.14 M(+23.9%) |
| June 2023 | - | -$25.41 M(+3.4%) | -$78.41 M(+1.6%) |
| Mar 2023 | - | -$24.57 M(+129.9%) | -$77.15 M(+4.8%) |
| Dec 2022 | -$73.59 M(+60.3%) | -$10.69 M(-39.8%) | -$73.59 M(-16.6%) |
| Sept 2022 | - | -$17.75 M(-26.5%) | -$88.21 M(+13.9%) |
| June 2022 | - | -$24.15 M(+14.9%) | -$77.47 M(+77.2%) |
| Mar 2022 | - | -$21.01 M(-16.9%) | -$43.73 M(-4.8%) |
| Dec 2021 | -$45.92 M(+224.4%) | -$25.30 M(+261.1%) | -$45.92 M(-370.8%) |
| Sept 2021 | - | -$7.01 M(-173.0%) | $16.96 M(+143.9%) |
| June 2021 | - | $9.59 M(-141.3%) | $6.95 M(-131.2%) |
| Mar 2021 | - | -$23.20 M(-161.7%) | -$22.25 M(+57.2%) |
| Dec 2020 | -$14.16 M(-79.6%) | $37.58 M(-320.9%) | -$14.16 M(-79.0%) |
| Sept 2020 | - | -$17.01 M(-13.2%) | -$67.54 M(-7.0%) |
| June 2020 | - | -$19.61 M(+29.8%) | -$72.62 M(+6.0%) |
| Mar 2020 | - | -$15.11 M(-4.4%) | -$68.53 M(-1.4%) |
| Dec 2019 | -$69.52 M | -$15.80 M(-28.5%) | -$69.52 M(+5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$22.10 M(+42.4%) | -$66.00 M(+12.3%) |
| June 2019 | - | -$15.52 M(-3.6%) | -$58.77 M(+12.7%) |
| Mar 2019 | - | -$16.10 M(+31.0%) | -$52.13 M(+7.5%) |
| Dec 2018 | -$48.51 M(+149.5%) | -$12.29 M(-17.3%) | -$48.51 M(+18.2%) |
| Sept 2018 | - | -$14.86 M(+67.4%) | -$41.03 M(+36.5%) |
| June 2018 | - | -$8.88 M(-28.9%) | -$30.05 M(+26.2%) |
| Mar 2018 | - | -$12.48 M(+159.4%) | -$23.82 M(+22.5%) |
| Dec 2017 | -$19.44 M(+115.3%) | -$4.81 M(+23.7%) | -$19.44 M(-3.8%) |
| Sept 2017 | - | -$3.89 M(+47.1%) | -$20.20 M(+4.2%) |
| June 2017 | - | -$2.64 M(-67.4%) | -$19.38 M(+28.6%) |
| Mar 2017 | - | -$8.10 M(+45.4%) | -$15.07 M(+66.9%) |
| Dec 2016 | -$9.03 M(-6.8%) | -$5.57 M(+81.3%) | -$9.03 M(+47.7%) |
| Sept 2016 | - | -$3.07 M(-284.1%) | -$6.11 M(+25.5%) |
| June 2016 | - | $1.67 M(-181.2%) | -$4.87 M(-47.1%) |
| Mar 2016 | - | -$2.06 M(-22.5%) | -$9.21 M(-5.0%) |
| Dec 2015 | -$9.69 M(-166.4%) | -$2.65 M(+44.8%) | -$9.69 M(+37.7%) |
| Sept 2015 | - | -$1.83 M(-31.3%) | -$7.04 M(+35.1%) |
| June 2015 | - | -$2.67 M(+4.8%) | -$5.21 M(+104.8%) |
| Mar 2015 | - | -$2.54 M | -$2.54 M |
| Dec 2014 | $14.60 M(-351.9%) | - | - |
| Dec 2013 | -$5.80 M | - | - |
FAQ
- What is AnaptysBio annual cash flow from operations?
- What is the all time high annual CFO for AnaptysBio?
- What is AnaptysBio quarterly cash flow from operations?
- What is the all time high quarterly CFO for AnaptysBio?
- What is AnaptysBio quarterly CFO year-on-year change?
- What is AnaptysBio TTM cash flow from operations?
- What is the all time high TTM CFO for AnaptysBio?
- What is AnaptysBio TTM CFO year-on-year change?
What is AnaptysBio annual cash flow from operations?
The current annual CFO of ANAB is -$120.80 M
What is the all time high annual CFO for AnaptysBio?
AnaptysBio all-time high annual cash flow from operations is $14.60 M
What is AnaptysBio quarterly cash flow from operations?
The current quarterly CFO of ANAB is -$10.09 M
What is the all time high quarterly CFO for AnaptysBio?
AnaptysBio all-time high quarterly cash flow from operations is $37.58 M
What is AnaptysBio quarterly CFO year-on-year change?
Over the past year, ANAB quarterly cash flow from operations has changed by +$24.26 M (+70.63%)
What is AnaptysBio TTM cash flow from operations?
The current TTM CFO of ANAB is -$103.01 M
What is the all time high TTM CFO for AnaptysBio?
AnaptysBio all-time high TTM cash flow from operations is $16.96 M
What is AnaptysBio TTM CFO year-on-year change?
Over the past year, ANAB TTM cash flow from operations has changed by +$17.79 M (+14.72%)